Tyra Biosciences, a clinical-stage biotech company specializing in precision medicines targeting FGFR biology, announced its participation in the Cantor Global Healthcare Conference 2026. The company will present via a virtual fireside chat and one-on-one investor meetings on September 9, 2026. Tyra is developing several clinical-stage drug candidates, including dabogratinib, TYRA-430, and TYRA-200, aimed at treating cancers and genetic conditions by selectively inhibiting FGFR pathways. Investors can access the live webcast on Tyra's website, highlighting the company's innovative SNÅP platform for rapid drug design and its pipeline's potential impact on oncology and genetic diseases.
Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...
Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...
The Trade Desk is undergoing restructuring with a 15% workforce reduction costing up to $51 million, following its removal from the S&P 500 index which caused a 2% stock drop. Despite these challenges, the company shows strong financial health, repor...
GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...
OpenAI announced that its AI systems solved the Navier-Stokes problem, a major unsolved math puzzle challenging scientists for nearly 100 years. Using about 10,000 AI agents working simultaneously, the solution was reached in 88 hours and verified in...
